Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Despite the increasing knowledge with regard to IBD (inflammatory bowel disease), including ulcerative colitis (UC) and Crohn's disease (CD), the etiology of these conditions is still not fully understood. Apart from immunological, environmental and nutritional factors, which have already been well documented, it is worthwhile to look at the possible impact of genetic factors, as well as the composition of the microbiota in patients suffering from IBD. New technologies in biochemistry allow to obtain information that can add to the current state of knowledge in IBD etiology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230670 | PMC |
| http://dx.doi.org/10.3390/nu14122520 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series.
Aliment Pharmacol Ther
July 2025
Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission.
View Article and Find Full Text PDFEvaluating a novel intestinal tampon for adults with ileostomy: pilot study.
Br J Nurs
September 2025
Professor, Department of Digestive Diseases, Transplantation and General Surgery, Copenhagen University Hospital Rigshospitalet/Department of Clinical Medicine, University of Copenhagen, Denmark.
Introduction: Approximately 1 million people live with ileostomies and rely on stoma bags in their daily lives. They do not have access to alternative products. To address alternatives, InterPoc™, an absorbent intestinal tampon, has been developed.
View Article and Find Full Text PDF99mTc-Labeled Cefixime for Targeted Imaging of Infections: Preclinical Evaluation and Potential in Postpartum Women.
Infect Disord Drug Targets
September 2025
Department of Chemistry, NFC Institute of Technology, Multan, Pakistan.
Introduction: Targeted infection imaging is crucial for accurate diagnosis in postpartum women. This project uses 99mTc-labeled cefixime to develop a radiopharmaceutical for detecting, distinguishing, and treating infections and abscesses in women.
Method: Technetium (TcO4-) chelated with cefixime, reduced by stannous chloride, confirmed via thin-layer chromatography.
Drug Delivery Strategies for the Lower GI Tract: A Review.
Adv Healthc Mater
September 2025
Smart Polymeric Biomaterials Research Group, Campus Group T, KU Leuven, Andreas Vesaliusstraat 13, Leuven, 3000, Belgium.
The lower gastrointestinal (GI) tract is affected by a range of diseases, including colorectal cancer and inflammatory bowel disease, among others. Effective treatment of these conditions requires drug delivery systems (DDSs) capable of precise targeting. While pH- and enzyme-sensitive DDSs are the most used, they often suffer from premature drug release and target specificity, limiting their efficacy.
View Article and Find Full Text PDFInflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomy.
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.
Materials And Methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs.